
price data provid thomson reuter
number may add due round
initi outperform pipelin product
initi coverag inc outperform rate
target repres newer addit public market follow octob
ipo howev origin spin-out medimmune/astrazeneca
compani hold consider institut knowledg expertis lead
asset inebilizumab review treatment neuromyel optica
spectrum disord nmosd pdufa see inebilizumab
pipelin within product assum success nmosd mg total
revenu reach beyond inebilizumab hold addit asset
current execut seven clinic program runway extend
multipl near-term catalyst includ nmosd pdufa phase
data lupu like setup share
inebilizumab differenti asset inebilizumab target
monoclon antibodi attempt deplet somewhat differ subset
cell therapi rituximab autoimmun disord
neuromyel optica spectrum disord nmosd aberr signal lead
secret pathogen autoantibodi lead tissu damag
inflamm drug target cell express
broader permit target plasmablast may contribut
pipelin product pipelin beyond first act
inebilizumab nmosd see numer autoimmune/inflamm
condit like address type therapi pivot n-
momentum studi demonstr inebilizumab reduc risk nmosd
attack overal patient initi revenu
estim assign credit sole inebilizumab initi nmosd
subsequ approv myasthenia gravi mg assum initi price point
per patient per year think indic gener
total revenu collabor hansoh mitsubishi bring access
asian market leav eu region upsid estim
near term catalyst like setup report interim data
phase studi lupu yet see initi dose data
monoclon antibodi see potenti read
recent lilac studi readout addit data tent track
third dose cohort howev think situat may remain fluid
amidst closur final inebilizumab nmosd pdufa remain
track target assum success inebilizumab nmosd
mg see downsid risk level inebilizumab realiz
delay howev major seven clinic program yet
valuat multipl upsid lever exist bottom line good combin
asset cash runway catalyst like setup share
initi outperform
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
tabl content
nmosd
nmosd similar multipl sclerosi
nmosd get treatment
nmosd develop landscap much horizon
newer agent enter treatment paradigm
inebilizumab first act nmosd beyond
nmosd inebilizumab weve seen far
inebilizumab myasthenia gravi mg weve seen far
might mg treatment landscap evolv
pipelin product pipelin
lupu proof-of-concept
valuat deep dive examin vs macro backdrop
minut macro biotech valuat
tabl figur
figur frequenc initi nmosd event
figur characteristics/comparison nmosd ms
figur comparison nmosd therapi market develop
figur inebilizumab mechansim action
figur comparison attack probabl n-momentum open-label extens
figur mechan action inebilizumab vs
figur select mg therapi clinic develop
figur comparison attack probabl n-momentum open-label extens
figur cell express chang diseas sjgren syndrom
figur effect rituximab diseas respond ri
figur overview interferon-driven pathogenesi sle
figur chang pdc count singl dose
summari conclus initi coverag outperform rate
target repres newer addit public market follow octob ipo
howev origin spin-out medimmune/astrazeneca compani hold
consider institut knowledg expertis lead asset inebilizumab review
treatment neuromyel optica spectrum disord nmosd pdufa
see inebilizumab pipelin within product assum success nmosd mg
total revenu reach beyond inebilizumab hold addit asset
current execut seven clinic program runway extend
multipl near-term catalyst includ nmosd pdufa phase data lupu
like setup share element thesi follow
said simpli see inebilizumab offer differenti profil term efficaci safeti
dose inebilizumab monoclon antibodi origin develop
medimmune/astrazeneca initi studi medimmune/astrazeneca brought forth
inebilizumab potenti treatment variou oncolog indic drug
deplet aberr cell contribut attack nativ tissu target
full continuum cell plasma cell cell still gener pathogen
autoantibodi extent diseas control therapi exert ultim
limit enter inebilizumab express occur cell subset
plasma cell thu hypothes robust impact autoantibodi product
pipelin product pipelin
present inebilizumab review approv neuromyel optica spectrum disord
nmosd pdufa date pivot n-momentum studi demonstr
inebilizumab reduc risk nmosd attack overal patient
studi focus broader popul evalu alxn soliri like
chanc broader label permit adopt earlier treatment journey beyond
nmosd plan initi pivot studi myasthenia gravi mg base preliminari
vitro data safeti profil date rituximab experi also think strong
likelihood success anticip inebilizumab nmosd launch commenc
assum launch mg total revenu reach
inebilizumab target central pathway affect rang autoimmun disord potenti
breadth use appear quit larg also pursu addit studi compani
root medimmun broaden opportun addit program
target indic sjgren syndrom kidney transplant bottom line fulli
amidst new normal still like risk/reward setup
complex undoubtedli creat challeng launch landscap
inebilizumab receiv approv june nevertheless think drug dose profil
also well receiv compani price product rang per
patient per year think still offer meaning discount rel alxn soliri
estim total revenu respect estim
assign credit inebilizumab nmosd mg leav remain five develop
program upsid current estim current cash provid runway
think compani well posit weather potenti delay may aris
numer upsid lever avail like current setup
figur illustr current develop pipelin march note
advanc pipelin effort center upon inebilizumab human
monoclon antibodi current review approv fda treatment
neuromyel optica spectrum disord nmosd current prepar addit
pivot myasthenia gravi mg studi base convers manag
believ studi still track initi recruit howev think
situat may fluid follow spin-out azn/medimmun pipelin
autoimmune/inflamm condit cutan lupu erythematosu see figur
note enter collabor agreement hansoh mitsubishi develop market
inebilizumab china hong kong macau japan asian region respect one six
potenti indic studi on-going phase multipl ascend dose studi system lupu
erythemat sjgren syndrom system sclerosi polymyos dermatomyos
tabl summar relev catalysts/data mileston relev vie
develop strategi deem like potenti impact share
impact near term potenti approv lead asset inebilizumab
treatment nmosd compani note pdufa remain track
addit process initi numer clinic trial inebilizumab
earlier-stag candid follow complet phase dose-escal
describ detail herein deriv price target share primarili
use sum-of-part dcf analysi valuat methodolog examin cash flow
gener per-product basi inebilizumab complement primari analysi also
examin potenti fair valu use compar multipl valuat approach price-to-earnings
p/ put initi result context howev import note believ sum-of-
part dcf strategi repres rigor approach development-stag and/or earli
commercial-stag biotech limit earn histori commerci experi tabl
illustr overal valuat contribut specif program well vie
current net cash pro forma basi
nmosd
neuromyel optica spectrum disord nmosd rare autoimmun diseas central
nervou system character inflamm optic nerv optic neuriti spinal
cord myeliti essenti immun system mediat inappropri attack bodi
healthi tissu optic nerv spinal cord lead format
lesion lesion disrupt proper signal lead variou debilit symptom
includ blind muscl weak paralysi fatigu pain figur shown
illustr variou diseas pathophysiolog mechan play
target pharmacolog
weinshenk wingerchuk
nmosd repres spectrum disord impli rang differ type clinic
manifest initi nmosd attack somewhat variabl term site
attack type tissu target figur shown provid breakdown
frequenc differ type initi nmosd event report result
deriv retrospect analysi nmosd patient interestingli transvers myeliti
commonli observ initi event optic neuriti present initi
nmosd patient see
figur frequenc initi nmosd event
optic neuriti start pain insid eye may lead loss visual acuiti
typic one eye affect howev case eye affect
simultan myeliti inflamm impact motor sensori autonom function
patient may suffer pain spine limb mild sever paralysi limb
loss bowel bladder control addit deep tendon reflex exagger
diminish initi exagger later period follow initi attack may
week month anoth episod occur howev indic disabl
cours diseas attack typic unpredict caus perman
damag lead long-term disabl death
nmosd similar multipl sclerosi
origin nmosd thought variant multipl sclerosi ms nmosd ms
demyelin condit overlap symptom make obtain proper
nmosd diagnosi signific challeng mani case issu perhap signific
diseas set particularli ms therapi exacerb nmosd
symptom thu need discrimin two condit import
tabl shown attempt compar canon featur
nmosd occur greater frequenc femal patient vs male slightli older
popul median age vs year unlik ms nmosd lesion typic form
brain early-stag
figur characteristics/comparison nmosd ms
nmosd get treatment
challeng discern nmosd ms patient receiv diagnosi
nmosd updat diagnost criteria publish part due identif
antibodi contribut diseas channel that highli
concentr region spinal cord nmosd attack loss
express due target pathogen anti-igg backdrop
current nmosd diagnosi util follow framework
prasad chen
present alxn soliri repres first drug formal approv treatment
nmosd specif indic patient posit antibodi
nmosd patient therapeut manag nmosd also incorpor high-dos intraven
corticosteroid methylprednisolon acut attack plasma exchang also use
manag acut attack patient fail respond intraven corticosteroid longer-
term diseas manag varieti immunosuppress drug corticosteroid
azathioprin mycophenol rituximab wide prescrib symptom manag
also involv low dose carbamazepin help control spasms/spast develop
patient motor deficit
nmosd repres rare diseas vari rate preval depend geograph
region addit chang diagnost criteria also impact estim present
guthi jackson foundat estim roughli nmosd patient within us
manag indic may closer patient remain conserv
in-lin project diseas appear preval individu african
asian pacif island polynesian caribbean descent specif treatment approv
 soliri diagnost criteria incorpor disease-relev biomark believ
size market opportun increas time diseas awar build
commun screen implement
nmosd develop landscap much horizon
newer agent enter treatment paradigm
recent approv alxn soliri mark import point nmosd patient howev
note sever potenti agent near regulatori decis roch satralizumab
human monoclon antibodi target receptor current review
fda tabl compar contrast versu roch
alxn
figur comparison nmosd therapi market develop
note baselin soliri median valu mean report uti multipl categori
infect report overal rate consist placebo
compar agent term efficacy/safeti inher studi design make
true direct comparison somewhat challeng exampl restrict
background immunosuppress therapi soliri studi howev permit
inebilizumab trial see thu soliri demonstr fewest proport
relaps apples-to-appl comparison versu other satralizumab
inebilizumab think latter featur stringent relaps definit lower rate
seriou advers event notabl inebilizumab may hold advantag infect rate
although await clariti label see transpir
inebilizumab first act nmosd beyond
inebilizumab human monoclon antibodi bind b-cell
act deplet upon bind see figur inebilizumab recruit
effector immun cell nk cell macrophag free fc region
effector cell bind fc portion elimin target cell elimin b-cell
rational auto-antibodi product b-cell mediat process lower
figur inebilizumab mechansim action
note previou name inebilizumab
uniqu inebilizumab target beyond target differ
molecul soliri satralizumab inebilizumab uniqu term engag
target herbst colleagu demonstr lack fucos sugar moieti fc portion
inebilizumab enhanc target affin antibody-depend cell-medi cytotox
adcc potenc antibodi maintain fucos remov
sugar residu allow fc region antibodi greater abil attract effector
immun cell nk cell macrophag etc elimin target figur
demonstr vitro system compar rituximab shown
roughli one log greater enhanc adcc inebilizumab compar rituximab control
antibodi triangl contain fucosyl fc region see adcc significantli declin
nmosd inebilizumab weve seen far
origin develop medimmun acquir inebilizumab astrazeneca azn
azn preliminari inebilizumab clinic effort focus target molecul toward variou
oncolog indic cll howev pursu distinct clinic path
molecul submit biolog licens applic bla august base
result pivot n-momentum trial random double-blind placebo-
control phase studi overal n-momentum enrol subject figur
illustr studi design briefli subject random either intraven
inebilizumab placebo administ day total combin dose given
primari endpoint trial time day onset adjud nmosd attack
inebilizumab met primari endpoint popul overal popul
post reduc risk nmosd attack rel placebo respect
studi halt complet enrol due clear sign efficaci
open-label portion n-momentum studi remain on-going approxim
subject enter portion trial shown figur note
subject receiv inebilizumab start studi probabl attack
continu higher compar placebo subject one year vs recal
end random period two group display similar differ vs
figur comparison attack probabl n-momentum open-label extens
inebilizumab myasthenia gravi mg weve seen far
nmosd indic repres advanc effort inebilizumab role
 cell autoimmun disord increasingli recogn import potenti
therapeut target recal cell primarili respons drive humor immun via
product antibodi irregular immun respons seen nmosd seen
condit like ms mg cell abnorm produc antibodi target critic
ms particular therapeut antibodi target antigen specif
 cell trigger b-cell kill
mg also driven abnorm autoantibodi product diseas set target
acetylcholin receptor also activ complement cascad rituxan rituximab
one exampl b-cell target therapi use refractori mg set
direct cytolyt antibodi howev note control studi rituximab
conduct one open-label studi refractori mg rituximab administ
repeat cycl subject assess use manual muscl test mmt mean
follow-up time month mean mmt score improv declin improv move
baselin valu point point studi assess
minimum improv differ mid mmt howev note
concomit reduct daili steroid usag
take-away anecdot report rituximab mg target
antibodi toward mg one strategi b-cell subset express
antigen cours matur antigen preval thu may
repres appropri target mg
figur mechan action inebilizumab vs
base review literatur check-in neurologist think target
may offer improv rituximab efficaci addit rituximab hold safeti
profil featur black box warn think physician patient would also welcom
altern option offer improv safety/toler base preliminari
preclin clinic profil observ inebilizumab think mg opportun
repres promis one furthermor see rapid uptak alxn soliri good
indic demand exist new therapi space
might mg treatment landscap evolv
rituxan use off-label mg treatment anecdot studi report
success outcom replic
random control studi
addit introduct soliri treatment gmg well receiv due
price point see adopt larg refractori patient backdrop
manag initi pivot studi mg current plan stage
landscap mg therapi develop becom crowd recent period
base kol convers impact potenti clinic trial site
think enrollment/recruit competit
figur shown illustr current therapi develop mg near term
anticip top-lin phase data ascend mg studi anti-fcrn
aggreg select studi enrol mg subject
figur select mg therapi clinic develop
note outcom list secondari measur safeti primari outcom
pipelin product pipelin
advanc effort pipelin center inebilizumab nmosd mg
howev compani current hold four phase program associ
inebilizumab addit compani monoclon antibodi
current phase studi look closer effort potenti
opportun effort remain upsid current estim figur illustr
cluster focu program focus signal pathway underli
rang disord product potenti applic across differ diseas beyond
initi effort neuroinflamm group increment opportun explor
peripher diseas well sjgren syndrom
figur comparison attack probabl n-momentum open-label extens
diseas inflammatori condit occur plasma cell invad
differ tissue/organ site cell gener sclerot mass rang clinic
manifest initi descript diseas pancrea frequent affect
site diseas known autoimmun pancreat although perhap less well-
known condit awar appear increas estim us preval
rang patient
similar diseas pathophysiolog autoimmun condit activ cell also
thought contribut diseas progress diseas shown figur
one clinic report examin patient sjgren syndrom diseas
found significantli higher subset cell patient diseas versu
sjgren syndrom healthi control given role impact inebilizumab
 cell would suggest potenti effect diseas
figur cell express chang diseas sjgren syndrom
note percent express among cell percent express among cell
diseas current treat accord intern consensu
guidanc patient subclin diseas may still requir treatment
consequ certain organ system among patient activ diseas
uncontrol first-lin treatment involv use glucocorticoid prednison
induc remiss treatment includ mechan intervent stent
use appropri remain unmet need new treatment diseas
preliminari effort cell-deplet therapi like rituximab
pilot trial rituximab research evalu three co-primari measur efficaci
absenc diseas flare month
glucocorticoid use month
studi show patient achiev primari endpoint shown figur
trend declin respond index score occur persist cours year
see
figur effect rituximab diseas respond ri
note correspond ri includ serum wherea post hoc analysi
serum exclud ri
steroid spare occur particip remain prednison
month assess studi note two patient hospit infect
cours pilot studi think underscor risk associ regimen
may creat opportun newer therapi improv
also pursu develop diseas treatment novel antibodi
known obexelimab obexelimab monoclon antibodi target
fcriib phase studi patient diseas obexelimab decreas
cell popul baselin see figur within studi patient
complet trial remiss achiev patient continu
monitor program potenti point differenti versu inebilizumab
surfac think bode well term valid target mechan
figur obexelimab pharmacodynam diseas
viela plan initi phase trial evalu inebilizumab treatment
diseas step back strategi use b-cell reduc agent appear
sound treat diseas base prevail evid similar therapi
inebilizumab show robust safeti profil date like set-up
lupu proof-of-concept
previous mention conduct dose-escal phase studi
patient system cutan lupu erythematosu sle cle human
monoclon antibodi target cell surfac molecul locat surfac
certain group cell known plasmacytoid dendrit cell pdc bone marrow-deriv
cell particularli relev lupu signal pathway respons
overproduct type interferon pro-inflammatori cytokin
attempt address hypothesi deplet pdc accumul
tissu lupu patient determin whether yield reduct result
inflamm tissu damag seen diseas see figur interestingli look
antibodi target pdc potenti insight
feasibl approach although focus protein antibodi seek
deplet pdc
figur overview interferon-driven pathogenesi sle
decemb announc primari endpoint met phase lilac studi
lupu patient see link among cle patient enrol studi report
reduct clasi-a score
dose drug compar reduct placebo
reduct meaning term magnitud benefit
interest read chang observ pdc improv skin
lesion via histolog lupu complic disord think multipl
contributor influenc product think data good first step
toward valid target
yield similar reduct pdc improv clasi score current
phase studi evalu three differ dose cohort data first cohort
alreadi gener yet publish manag previous
describ gener safe reduc pdc count plasma data cohort
anticip report third final cohort still track
data studi enrol total subject total subject second
third cohort
term look data think three thing notabl first
show declin circul pdc follow singl dose see
interest see similar declin cell plasma and/or tissu occur
describ chang observ cohort look data phase
studi compar figur depict chang circul pdc follow singl
dose addit declin observ would also expect see effect
figur chang pdc count singl dose
second given scope enrol subject phase studi power show statist
differ clasi score nevertheless would also look see trend toward
improv respond third still one higher dose cohort
still complet focus safety/toler profil advers event
present administ once-monthli inject
estim lupu patient within us accord lupu foundat
america sle cle popul account total popul either
indic would larg opportun pursu particularli contrast
nmosd note compani yet select lead indic pursu
current phase studi see basket trial also encompass
patient sjgren syndrom scleroderma dermatomyos bottom line think
preliminari phase data help inform whether hold activ molecul
direct pursu clinic campaign await clariti manag
data emerg
follow section describ detail current market model inebilizumab
nmosd market addit although pivot studi anticip begin
given pre-clin profil safeti profil establish date also assign credit
gmg opportun well remain indic asset await addit
clinic data assign formal credit note preliminari phase interim data
cutan lupu erythematosu still anticip
figur illustr market model inebilizumab nmosd market recal
bla current review fda pdufa date assign
base recent convers manag continu see agenc stay
track current timelin base data variou compani roch
estim approxim us nmosd patient among overal popul
estim receiv formal diagnosi see figur segment
market opportun estim approxim elig treatment yield
address us market opportun nmosd patient
yet assign credit nmosd indic eu market
ex-u infrastructur present unclear seek partner asset howev
think opportun estim similar market segment assum
preval eu popul encompass patient compani agreement
hansoh mitsubishi bring access select asian market japan repres
larg opportun estim japanes nmosd popul patient
disclos specif around royalti rate trigger escal thu model repres
best estim await addit visibl note nmosd patient
thought seroposit antibodi evalu posit neg
subject studi assum broader product label compat popul
present assum on-tim approv decis earliest commerci launch
commenc compani opin potenti price inebilizumab
stage current estim assum price consist orphan therapi
figur summar price assumpt project gross annual price
per patient appli appropri price complianc discount estim
net annual price point per patient see figur roche/chugai
product may also gain approv see inebilizumab well posit commerci
landscap particularli regard infect rate efficaci
price assumpt compar alxn soliri assum annual inebilizumab
price like substanti discount rel annual soliri price base
current soliri label model net price per patient per year around assum
broader label inebilizumab look beyond patient constraint
underlying/baselin therapi inebilizumab popul like shift toward earlier
line treatment compar soliri final inebilizumab dose follow less frequent
paradigm two load dose day apart follow mainten infus everi
month compar infus dose soliri see type format lead
higher degre complianc among patient perhap also greater willing seek
figur illustr market model inebilizumab mg market pivot
studi set begin anticip commerci entri
myasthenia gravi foundat america estim mg
patient us incorpor estim mg patient model
continu await detail propos phase trial design segment
market focu mg patient achr patient final address us market
opportun patient see figur appli similar price assumpt
inebilizumab mg market nmosd market project similar dose
framework incorpor
valuat deep dive examin vs macro backdrop
minut macro biotech valuat
tabl summar current valuat metric large-cap mid-cap
commerci stage biotechnolog compani see relev futur peer group
current mid-cap commerci group highlight figur mid-cap
commerci peer group current trade mean consensu revenu median
note price
repres somewhat unpreced time recent market
upheav retrac backdrop note rel
biotech peer group histor trade premium multipl note sinc
large-cap biotech peer group trade discount broader market howev amidst
start pandem biotech sector began see increas sector-level
price-to-earnings multipl compar see figur
recal complet ipo octob thu compani overal trade
histori somewhat condens lock-up period tie ipo expir
anticip futur inflect point share larg coincid data result strateg
announc competit updat look ahead near term see regulatori
updat associ inebilizumab impact stock primari valuat
deriv sum-of-part dcf analysi focus potenti cash flow
inebilizumab discount back per year base compani approach transit
toward commerci statu figur illustr per-product contribut well
current net cash per share
beyond primari valuat analysi also examin altern valuat
methodolog triangul current price target note approach
also sensit select discount rate multipl valuat year figur
illustr potenti fair-valu estim deriv use respect approach
compar primari target share deriv via sum-of-part dcf analysi
select valuat year p/ price-to-earnings analys see prior figur
like repres steady-st period revenu growth compar potenti period
inebilizumab launch phase addit adher discount rate also
consist rate use primari valuat methodolog appropri pre-
around consensu earn appli discount multipl rel large-cap
peer group given absenc posit histori earn stage
likewis current mean peer revenu multipl rang consensu revenu
mid-cap large-cap group p/ valuat analysi select revenu
multipl essenti in-lin versu mid-cap commerci peer group although vie
statu pre-commerci compani earlier see compani pipelin hold rang
asset market opportun meaning altern valuat deriv
fair valu estim primari method note primari
approach incorpor net cash
share current trade rang sinc compani ipo complet
share return nbi despit recent sell-off across equiti sector
associ pandem backdrop key near-term
catalyst inebilizumab pdufa examin potenti risk/reward setup share
depict figur see favor risk/reward setup share current
base case assum on-tim approv inebilizumab nmosd approxim
revenu first year continu see high unmet need space assum
broad prescrib label unfold think inebilizumab differenti asset
marketplac addit assign credit effort mg assum commerci
launch present await data addit opportun
relat diseas data inebilizumab proof-of-concept data assign
industri potenti
headwind affect nearli
consequ well exampl limit impos face-to-fac interact may
make commerci launch challeng drug novel mechan action
think physician see parallel rituximab infus schedul may
benefici push launch trajectori inebilizumab nmosd year lower
fair valu estim remov current net cash lower
current valuat ascrib credit nmosd opportun mg
repres larger proport loss nmosd program would ultim
lower fair valu close share current trade
see multipl driver potenti upsid rel current target first pipelin
expans key variabl multipl proof-of-concept studi across pipelin either
underway initi come month better inform potenti
strategi pursu model captur econom two seven
program see multipl opportun expand pipelin valuat second
market uptak also drive valuat higher previous state yet assign
credit eu market believ like cours action partnership
may opt expand infrastructur pursu commerci independ expand
nmosd mg opportun eu market increas target
exampl like conserv estim mani indic
pursu sjgren syndrom diseas encompass larger
prospect market opportun nmosd
note price
viela gaithersburg md-base pre-commerci biopharma focus
develop commerci novel therapi autoimmun sever
inflammatori disord launch spin-out medimmun
subsidiari astrazeneca compani launch earli becam publicli
trade entiti octob platform hous multipl medimmun asset
inebilizumab repres advanc program current review fda
approv treatment nmosd
overal see manag team hold extens experi expertis across
discoveri clinic develop commerci biopharmaceut product
describ review detail key member execut team
dr yao serv compani ceo sinc spun medimmun dr yao join
medimmun previous hold senior research roll genentech beyond
experi firm dr yao also held scientif roll aventi dr yao
receiv phd univers iowa
mr chan appoint role cfo previous serv director
investor relat astrazeneca prior role azn mr chan also held posit
increas respons genentech-roch mr chan receiv bsc
univers toronto
dr drappa current serv head research develop
join compani spin-out medimmun prior join
medimmun dr drappa serv medic director dr drappa receiv md
univers cologn germani phd cornel medic school hospit
ragatz vice-president head commerci
mr ragatz current serv head commerci effort prior join
team mr ragatz serv director astrazeneca led commerci strategi effort
azn anifrolumab remain develop mr ragatz receiv mba duke
univers fuqua school busi
meali wingerchuk greenberg levi epidemiolog
neuromyel optica unit state multicent analysi neurol
spectrum neuromyel optica lancet neurolog septemb pp
diagnost criteria neuromyel optica spectrum disord similar outcom
prasad chen need know mog nmosd semin
fujihara paul cutter marigni et al inebilizumab treatment
neuromyel optica spectrum disord n-momentum double-blind randomis
patti tsai -p saiz yamazaki et al trial satralizumab neuromyel
totolyan viswanathan et al eculizumab
antibodi treatment autoimmun neurolog diseas insight
preclin studi clin
pharmacolog profil novel antibodi
row cheng cook et al b-cell deplet vitro
pereira chan song less-is-mor therapeut
antibodi afucosyl anti-canc antibodi enhanc antibody-depend
cellular cytotox mab taylor franci inc juli pp
beecher siddiqi rituximab refractori myasthenia gravi
extend prospect studi result muscl nerv
respons myasthenia gravi neurolog clinic saunder may pp
dose rituximab treatment base assess circul cell patient
refractori myasthenia gravi ther adv neurol disord
hammer attract target antibody-bas therapi mab taylor
 cell subset dysfunct regulatori cell diseas primari
sjgren syndrom similar differ arthriti ther
statement manag treatment diseas arthriti
khosroshahi bloch deshpand stone rituximab therapi lead
rapid declin serum level prompt clinic improv
deshpand smyrk chari stone et al rituximab
amelior skin lesion system lupu erythematosu clin invest
target deriv sum-of-part dcf analysi potenti cash flow inebilizumab nmosd mg discount back
per year
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori may employ acceler strategi gain approv regul may requir addit data could alter
requir approv necessit addit longer studi
commerci failur execut commerci inabl meet/exce expect impact share inebilizumab
advanc commerci market repres compani first attempt market sell drug
competit updat competitor may posit neg impact share relev competitor includ compani
ucb roch xenon gener compani competitor like emerg time
may need access capit market advanc portfolio asset access capit market becom
constrain could limit abil continu develop commerci product
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
april
april
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
